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P. aeruginona infections need accurate antimicro-
bial susceptibility data, as treatment mainly relies on 
antibiotic efﬁ ciency in debilitated patients. Vitek 2, a 
popular automated susceptibility testing method, was 
compared with Etest to assess its reliability on 150 
Belgian P. aeruginonas isolates. 
Vitek 2 and Etest exhibited a high degree of con-
cordance, but some discrepancies in clinical category 
were evident for cefepime (high minor and borderline 
very major error rate) and for piperacillin/tazobactam 
(high very major error rate). Vitek 2 appears to yield 
valuable information to the clinician concerning the 
antimicrobials amikacin, ceftazidime, ciproﬂ oxacin 
and meropenem, in the setting of pseudomonas infec-
tion. For cefepime and piperacillin/tazobactam, a con-
ﬁ rmatory testing by means of disk diffusion is worth 
considering.
INTRODUCTION
Pseudomonas (P.) aeruginosa infections pose sev-
eral problems to the clinician.1,2 Most often, they occur 
in debilitated patients with severe underlying disease 
and disturbance of the host defence mechanisms.3,4 
Moreover, even sensitive strains usually exhibit MIC 
values close to the susceptibility breakpoint for any 
given antipseudomonal antimicrobial. Therefore, when 
reporting the in vitro susceptibility pattern of a P. aeru-
ginosa strain to the clinician, it is of utmost importance 
for it to be accurate. Moreover, most patients will large-
ly depend, rather than on their own defence system, on 
the antimicrobial activity of the agent(s) administered 
and on supportive care.
In Belgium, several teaching and large general hos-
pital laboratories make use of the Vitek 2 automated 
system (bioMerieux Vitek, Hazelwood, USA) for 
species identiﬁ cation and antimicrobial susceptibility 
determination. Several accuracy evaluations of Vitek 2 
have been published.2,4-14
One of the beneﬁ ts of this rapid test is provision of 
test information sooner so that changes in antibiotic 
therapy, when indicated, can be implemented more 
quickly.15 Vitek 2 offers a standardized method ideally 
suited to laboratories lacking familiarity with, myriad 
resistance mechanisms and/or those not testing an 
appropriate number, or range, of antibiotics to detect 
resistant phenotypes using interpretative reading of 
MICs.6 The Vitek Advanced Expert System comprises 
a database of MIC distribution for different combina-
tions of antibiotics and prevalent resistance mecha-
nisms in different species, together with a series of 
algorithms. Both, unlikely combinations of phenotype 
and species as well as inferred mechanisms predicting 
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clinical resistance to drugs to which bacteria appeared 
susceptible at breakpoint are highlighted.7 Although 
this system can provide results within 6 h, there are 
shortcomings. They can for instance misidentify cer-
tain clinically important mechanisms of antimicrobial 
resistance.8 Cell-wall active compounds like cefepime, 
ceftazidime, meropenem and piperacillin/tazobactam, 
used with an inappropriately high inoculum, cause 
higher MICs with the Vitek system when P. aeruginosa 
is tested.5,6 Vitek’s automated susceptibility testing re-
sults have previously shown to be very misleading for 
imipenem when testing P. aeruginosa.16 Other draw-
backs of automated systems are related to the narrow 
range of antibiotic concentrations included in the an-
timicrobial cards, which precludes the detection of re-
sistances expressed at a low level.8 Moreover, patients 
with cystic ﬁ brosis frequently have a unique P. aeru-
ginosa phenotype including the presence of mucoid 
exopolysacccharide and relatively slow growth rates 
in the laboratory, features which may make standard-
ized performance and interpretation of antimicrobial 
susceptibility testing difﬁ cult.11 
This report compares Vitek 2 with Etest (AB Bi-
odesk, Solna Sweden) susceptibility results using 150 
clinical P. aeruginosa isolates from 3 large-sized hos-
pitals. 
In case the overall very major error rate (susceptible 
result with Vitek 2 and resistant with Etest) was equal 
to or exceeded 1.5% for a speciﬁ c antibiotic (occurring 
for piperacillin/tazobactam and cefepime), the strains 
with this error occurring in at least two of the 3 partici-
pating hospitals were further analysed. At one centre, 
the Sensititre system (Trek Diagnostic Systems Inc, 
West Sussex, UK, providing quantitative susceptibility 
results in a dried panel format) was applied on these 
strains in order to reach a consensus result. 
MATERIALS AND METHODS
Each centre collected 50 consecutive non-dupli-
cate clinical P. aeruginosa strains, subsequently for-
warded its strains to the other two participating centres, 
each ﬁ nally disposing of 150 isolates to be tested. 
The following antibiotics were assessed: amikacin, 
cefepime, ceftazidime, ciproﬂ oxacin, meropenem and 
piperacillin/tazobactam.
Results were expressed in terms of clinical 
(Susceptible/Intermediate/Resistant) categories. For 
the whole collection, comparisons were made between 
both methods, as well as between centres considered 
separately.
Susceptibility testing with the Vitek 2 system was 
performed with standard European AST-N020 cards 
according to the following method. Strains were 
subcultured, subsequently grown in ambient air for 
18-24 h at 35°C on Tryptic Soy Agar containing 5% 
horse blood. Suspensions of these cultures were made 
in 0,45% saline, adjusted to the 0,5 McFarland turbid-
ity standard, and used to ﬁ ll the test cards for the Vitek 
2 instrument applied according to the manufacturer’s 
instructions.
The Vitek 2 system automatically measures a tur-
bidity signal for each test well containing an antibiotic, 
every 15 min for up to 18 h. These data are used to gen-
erate growth curves and by comparison with a control, 
the MIC of each antibiotic is estimated.
Each agent is included in the AST-N020 test card 
at two to four different concentrations: amikacin: 2-64 
µg/ml, cefepime and ceftazidime: 1-64 µg/ml, cipro-
ﬂ oxacin: 0.25-4 µg/ml, meropenem: 0.25-16 µg/ml, 
piperacillin/tazobactam: 4-128 µg/ml.
All results outside this range are reported as either 
the lowest or highest level available.
Susceptibility testing with Etest strips was per-
formed according to following method. Etests were run 
in parallel with MIC determinations on the Vitek 2 sys-
tem. The same subculture was used for both methods. A 
suspension of several well isolated P. aeruginosa colo-
nies was prepared from an overnight grown blood agar 
plate, with a turbidity adjusted to visually match that 
of the 0,5 McFarland turbidity standard. The six Etest 
strips, each containing a different antimicrobial agent, 
were placed radially on the surface of a large round 
Mueller-Hinton agar plate inoculated with the bacterial 
suspension. After incubation for 18 to 24 h in ambient 
air at 35°C, the MIC was read directly from a scale on 
top of the strip at the point where the edge of the inhibi-
tion ellipse intersects the side of the strip. 
Etest generates MIC values from a continuous 
scale (results in two-fold dilutions) and extending ei-
ther from 0.016 to 256 µg/ml (ceftazidime, amikacin, 
cefepime, piperacillin/tazobactam), or from 0.002 to 32 
µg/ml (ciproﬂ oxacin and meropenem).
Breakpoints for susceptibility category determina-
tion (Susceptible/Intermediate/Resistant) were those 
recommended by the NCCLS guidelines.17
Results were expressed in terms of MIC (µg/ml), 
translated into clinical categories (S/I/R) and differ-
ences between both methods were deﬁ ned as:
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. agreement in clinical category or ACC (result identi-
cal with both methods)
. minor error: S with Etest and I with Vitek or vice 
versa, R with Etest and I with Vitek or vice versa
.  major error: S with Etest and R with Vitek
. very major error: R with Etest and S with Vitek
When for a certain strain, a very major error was 
registered in at least two of the centres, Sensititre was 
performed as the reference broth microdilution method 
(NCCLS). The consensus result was deﬁ ned by the test 
corresponding with Sensititre, conform to Chandler’s 
performance study of the Vitek System (software ver-
sion VTKR07.01).12
Sensititre plate susceptibility testing was performed 
according to the following method. In demineralised 
water, 3 to 5 P. aeruginosa colonies from an overnight 
grown blood agar plate were suspended and adjusted 
to reach the 0.5 McFarland turbidity standard. 10 µl 
of the suspension was transferred into a tube of 11 ml 
cation-adjusted Mueller-Hinton broth. After vortex-
ing, 50 µl of this concentration was inoculated (using 
a multi-pipettor) into each of the wells. The plate was 
covered with an adhesive seal and incubated in ambient 
air at 35°C for 18-24 h. Growth appears as turbidity or 
as a deposit of cells at the bottom of a well. The MIC 
is recorded as the lowest concentration of antibiotic 
inhibiting visible growth. 
The dilution ranges available on the Sensititre 
plates are: amikacin: 4-32 µg/ml, cefepime: 2-16 µg/
ml, ceftazidime: 1-16 µg/ml, ciproﬂ oxacin: 0.25-2 µg/
ml, piperacillin/tazobactam: 8/4-64/4 µg/ml.
RESULTS
1. According to clinical categories.
Overall, the percentage of agreement in clinical 
category (ACC) between both methods was 91.15 %. 
There were 8.05 % minor errors, 0.57 % major er-
rors, 1.57 % very major errors and a total error rate of 
8.85 %.
Table 1, row 2-4 gives an overview of the com-
parative test results in all three centres analysed collec-
tively. For every antibiotic tested, the table shows the 
percentages of resistant, intermediate and susceptible 
strains with both methods. The last column represents 
the mean percentages of all antibiotics together.
The resistance of P. aeruginosa varied from less 
than 10% (amikacin with Etest, cefepime and mero-
penem with Vitek) to almost 30% (ciproﬂ oxacin, both 
methods). There were some differences between both 
methods. 
Every discrepancy in clinical category registered in 
a centre was counted as one error, independently of the 
result in the other two centres. 
Table 1, row 5-9 shows the concordance between 
both methods, for each antibiotic, expressed as either 
the rate of agreement in clinical category, or the error 
rate (minor, major, very major and total). The last col-
umn again shows the mean rate per error category for 
all antibiotics pooled.
Cefepime excepted, ACC exceeded 90% for all an-
timicrobial agents tested. Combined minor-major error 
rates are excessive (>7%) for amikacin, cefepime and 
ceftazidime. For cefepime, the low ACC was due to a 
high rate of minor errors and 1.50 % very major errors. 
No antibiotic exhibited a large number of major errors 
(> 3%), but piperacillin/tazobactam had an unaccept-
ably high frequency (6.20%) of very major errors. 
Piperacillin/tazobactam and cefepime, the two anti-
biotics with the highest rate of very major errors were 
further analysed with the Sensititre system.
Table 2 represents the results of Vitek 2, Etest and 
Sensititre method performed on the seven strains with 
a very major error between Vitek 2 and Etest in at least 
two of the three centres. 
Compared with Sensititre, Vitek 2 also showed very 
major errors for piperacillin/tazobactam in 6 of the 7 
strains with very major errors between Vitek2/Etest. 
Etest seemed to fall in the major error category just 
once with piperacillin/tazobactam. For the only very 
major error between Vitek 2 and Etest with cefepime, 
Sensititre gave consent to Etest.
2. According to the individual centres.
Table 3 describes the comparison between the 3 
centres, taken separately, in terms of clinical catego-
ries. Note that results have been calculated, using the 
same range distribution for both test methods. 
For all antibiotics pooled together, the distribution 
of errors in each of the error categories was highly con-
cordant between the three centres. One noticed a slightly 
increased percentage of major errors in one centre.
Table 4 describes the pattern of differences in re-
sults expressed as clinical categories (S/I/R) between 
both testing methods in all of the three centres: same 
error in all three, variable in all three, discrepancy only 
in one laboratory. All other strains tested, yielded fully 
concordant results.
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Table 1. Row 2-4: qualitative test results with Vitek 2 (V) and Etest (E), expressed as percentage of total; row 5-9: 
concordance between both methods.*
Amikacin
 V E 
(%)
Cefepime
 V E 
(%)
Ceftazidime
 V E 
(%)
Ciproﬂ oxacin
 V E 
(%)
Meropenem




 V E 
(%)
Mean
 V E 
(%)
R 11.75 8.55 9.62 15.63 13.89 14.13 27.14 28.27 8.33 10.28 11.97 17.95 13.78 15.80
I 4.06 5.34 11.97 11.35 11.54 5.57 7.91 5.35 6.20 4.71 -     -   6.94 5.39
S 84.19 86.11 78.42 73.02 74.57 80.30 64.96 66.38 85.47 85.01 88.03 82.05 79.27 78.81
ACC 91.67 84.58 90.36 93.15 93.58 93.59 91.15
Minor error 7.26 13.71 8.15 6.21 4.92 - 8.05
Major error 0.85 0.21 1.28 0.43 0.43 0.21 0.57
Very major 
error
0.22 1.50 0.21 0.21 1.07 6.20 1.57
Total error 8.33 15.42 9.64 6.85 6.42 6.41 8.85
R: resistant  I: intermediate  S: susceptible
*Calculations done after the ranges of both tests had been rendered identical; i.e. all Etest results below or beyond the Vitek range have 
been drawn level to the lowest or highest available Vitek dilution, respectively.
Table 2. Comparison Vitek 2 (V), Etest (E) and 
Sensititre (S) for strains with an excessive rate of very 







27 64 (S) >256 (R) >64 (R)
74 64 (S) >256 (R) >64 (R)
81 64 (S) >256 (R) 64 (S)
43 64 (S) 128 (R) >64 (R)
50 64 (S) 128 (R) >64 (R)
10 64 (S) >256 (R) >64 (R)
18 64 (S) >256 (R) >64 (R)
Cefepime
(8-32 µg/ml)
27 8 (S) 32 (R) >16 (R)
Table 3. Comparison of the results between the 3 cen-









ACC 91.24 91.08 91.13 91.15
Minor error 8.23 8.02 7.89 8.05
Major error 0.21 1.06 0.44 0.57
Very major error 1.69 1.17 1.86 1.57
Total error * 10.13 10.25 10.19 10.19
*: Note that the column “average” and the row “total error” don’t 
always add up arithmetically with the data of the table, as a result 
of rounding up, and that the sum of the ACC with the total error 
rate does not always equals 100 % because of absence of minor 
errors for piperacillin/tazobactam, changing the proportions of er-
ror rates.
The same error in all three labs appeared once with 
amikacin and twice with cefepime, ceftazidime, cipro-
ﬂ oxacin and piperacillin/tazobactam.
Variable patterns were observed between 1 and 8 
times with all antibiotics tested.
A discrepancy limited to one single laboratory ap-
peared between 12 and 33 times, a phenomenon which 
did not occur for ceftazidime. 
DISCUSSION
In order to assess the accuracy of Vitek 2 in the 
present setting, one can ﬁ rst perform an analysis by 
clinical category (R/I/S). Overall, the rate of agree-
ment between both methods was 91.15%. This means 
that there was a discrepancy of some kind between the 
results obtained with Vitek 2 and those obtained with 
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Etest in only 8.85%. Amongst these, one can distin-
guish between the so-called minor errors (8.05% in 
this study), whereby the results were within a category 
which was susceptible or resistant with one method 
and intermediate with the other method; major errors 
(0.57%) whereby the reference method indicates sus-
ceptibility and the test method resistance; and ﬁ nally, 
very major errors (1.57%) deﬁ ned as resistance with 
the reference method and susceptibility with the test 
method.18 Rationale behind this classiﬁ cation is that 
one does not want to treat patients with a potentially in-
active agent, in case the reference method would yield 
“resistance” whereas the test method would suggest 
susceptibility. 
However, strictly speaking, these terms have been 
coined in studies using broth microdilution as the refer-
ence method. In the present study though, Etest and not 
broth microdilution, played the role of method of refer-
ence. As such, the terms minor, major and very major 
errors could be of some impropriety.
An overall category error rate of < 10% has been 
established as a standard of performance for suscepti-
bility tests. Included in this target percentage are very 
major error rates of ≤ 1.5% and major error rates of ≤ 
3%.5,19 The pooled ﬁ ndings in this study complied with 
this expectation, except for a small excess of 1.57% 
very major errors. Elder recommended a combined ma-
jor-minor error rate of < 7%, which is only achieved for 
ciproﬂ oxacin, meropenem and piperacillin/tazobactam, 
when antibiotics were considered separately. 
If one considers the resistance rate expressed in 
clinical categories (see Table 1, row 2-4), 15% of 
P. aeruginosa isolates were found non-susceptible (re-
sistant plus intermediate) to amikacin, meropenem and 
piperacillin/tazobactam, 20% to cefepime and ceftazi-
dime, but in the case of ciproﬂ oxacin this rate reached 
almost 35%. These values are in agreement with the 
susceptibility pattern of this organism in Belgium.20 
When one analyses the concordance between both 
methods in terms of clinical categories according to 
the antibiotic tested (as in Table 1, row 5-9), the Vitek 
2 system appears to agree rather well with the Etest 
for most antibiotics (ACC over 90% conform Jor-
gensen’s criteria, major and very major errors within 
the limits), except for cefepime (84.58% ACC) and for 
piperacillin/tazobactam (6.20% very major errors). In 
the case of cefepime, there were 1.50% very major er-
rors, but the 13.71% minor errors were responsible for 
the largest portion of discrepancies between both meth-
ods. Chandler also reported of a 12.5% minor error rate 
for cefepime comparing Vitek 2 with disk diffusion 
and broth microdilution.12 He did not register very 
major errors for cefepime or piperacillin/tazobactam 
though. It is interesting to remark that minor errors 
can occur as a result of one dilution difference, the 
experimental error on the method. Vitek has shown 
routinely to produce more resistant results than broth 
microdilution for cefepime. Jones also compared Vitek 
versus Etest results for cefepime, with 18.3% minor 
errors and 3.3% major errors. He recommends Vitek 
users to use broth microdilution, disk diffusion or Etest 
to appropriately guide infection chemotherapy for 
gram-negative strains.13 The Vitek system (Vitek Card 
GNS-116) produced a high major error rate of 8.9% 
for meropenem compared with the broth microdilution 
reference method.2 On the other hand, Etest MICs for 
meropenem have shown to be signiﬁ cantly higher than 
broth microdilution MICs for P. aeruginosa isolates.2 
Similarly, Etest has recently been reported to yield 
more resistant results than other methods (e.g. broth 
dilution) when testing P. aeruginosa for susceptibility 
to cefepime.21 
In our study, Etest for cefepime showed in 6.85% 
(data not shown) of all strains more than one dilution 
greater MICs than Vitek, explaining the very major er-
rors. 
In the case of piperacillin/tazobactam, Table 1 shows 
a very major error rate of 6.20%. One of the reasons for 
Table 4. Distribution of similar versus variable differences in clinical categories among centres (in absolute num-
bers out of a total of 150 strains).
Amikacin Cefepime Ceftazidime Ciproﬂ oxacin Meropenem Piperacillin/
tazobactam
Similar in all 3 1 2 2 2 - 2
Variable 7 6 8 1 5 2
Only in one 14 33 - 13 12 16
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this ﬁ nding could be the absence of an “intermediate” 
category. Indeed, the NCCLS standards for this agent 
have been modiﬁ ed on several occasions in the last 2 
decades and the present susceptibility breakpoint for P. 
aeruginosa is different from that of other Enterobac-
teriaceae (64 µg/ml instead of 32 µg/ml).15 Sensititre 
was concordant with Etest in 6 of the 7 strains with 
piperacillin/tazobactam very major errors and in the 
only very major error with cefepime. Sensititre taken 
as consensus makes us suggesting that Etest and not 
Vitek 2 is more correct. 
Note, however, that the MIC ranges differed be-
tween both methods. As was detailed in the section ma-
terials and methods, the lowest and the highest avail-
able concentration of Etest exceeded those of Vitek 
2. For that reason, all calculations were done after the 
ranges of both tests had been rendered identical. This 
means all results of Etest below or beyond the Vitek 2 
range were considered equal to the lowest or highest 
(respectively) Vitek 2 dilution available. 
In order to explain the few differences observed, one 
could compare the results obtained in every particular 
centre, to make sure the overall results apply locally on 
the one hand, and in an effort to explain the less favour-
able results in terms of the low ACC for cefepime and 
the very major errors for piperacillin/tazobactam.
Table 3 indicates that all three centres performed 
roughly as well, overall, with an ACC exceeding 90% 
and with a very major error rate slightly augmented in 
two centres.
Discrepancies between methods can be inherent to 
the methods themselves, or they can be the result of 
some interpretative problems by the laboratory person-
nel and/or the reporting microbiologist. For this reason, 
table 4 analyses the repetitive character of discrepan-
cies. It shows that the same difference in clinical error 
categories only was found in a very limited number of 
cases in all three participating laboratories: never with 
meropenem, once with amikacin and twice with the 
other antibiotics. In those cases, one might conclude 
both methods yielded somewhat different results. In 
instances with variable patterns of differences between 
the individual laboratories, one might be tempted to 
think they were due to human “errors” rather than to 
intrinsic methodological differences.
In conclusion: the 150 clinical strains studied in 
this report exhibited a susceptibility pattern similar to 
other recent collections in Belgium, irrespective of the 
testing method. By and large, Vitek 2 showed high con-
cordance with Etest, meeting the criteria for accuracy. 
Some differences did occur in ACC for cefepime. Very 
major errors were registered in excess for piperacillin/
tazobactam. They seem to be due to some difﬁ culty in 
interpreting Etest in individual centres. The same er-
ror very rarely occurred in the 3 centres. The overall 
accuracy of the Vitek 2 system exceeded 91%, with 
only cefepime not reaching the acquired 90% of ACC 
(84.58%). 
Vitek 2 appears to yield valuable information to 
the clinician concerning the antimicrobials amikacin, 
ceftazidime, ciproﬂ oxacin and meropenem, in the 
setting of P. aeruginosa infection. For cefepime, and 
piperacillin/tazobactam, a conﬁ rmatory testing by 
means of disk diffusion is worth considering.
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SAMENVATTING
Pseudomonas aeruginosa infecties bij ernstig 
verzwakte patiënten vereisen accurate antimicrobiële 
gevoeligheidsgegevens, aangezien hun behandeling 
voornamelijk gebaseerd is op antibiotische efﬁ ciën-
tie. Vitek 2, een populaire geautomatiseerde gevoe-
ligheidsmethode, werd vergeleken met Etest om zijn 
betrouwbaarheid te evalueren op 150 Belgische P. 
aeruginona isolaten. 
Vitek 2 en Etest vertoonden een hoge mate van con-
cordantie. Discrepanties in klinische categorie werden 
vastgesteld met cefepime (meer mineure fouten en 
maximaal toegelaten percentage zeer grote fouten) en 
met piperacilline/tazobactam (meer zeer grote fouten). 
Bij pseudomonas infecties blijkt Vitek 2 de clinicus 
waardevolle informatie te leveren voor de antibiotica 
amikacine, ceftazidime, ciproﬂ oxacine en meropenem. 
Voor cefepime en piperacilline/tazobactam valt een 
bijkomende conﬁ rmerende disk diffusie test te over-
wegen.
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